CYCC - Cyclacel Pharmaceuticals GAAP EPS of -$0.42 beats by $0.14
- Cyclacel Pharmaceuticals press release ( NASDAQ: CYCC ): Q3 GAAP EPS of -$0.42 beats by $0.14 .
-
- Net loss for the three months ended September 30, 2022, was $5.1 million, compared to $5.0 million for the same period in 2021.
For further details see:
Cyclacel Pharmaceuticals GAAP EPS of -$0.42 beats by $0.14